The current global framework for supporting R&D for new medicines is myopically and wrongly focused creating obligations to grant and expand monopolies on products (through patents and other intellectual property and regulatory measures) and weakening government cost control measures. The Delinkage models would replace the monopoly and high prices paradigm with a program of cooperation in funding R&D, outside of the framework of high prices.
On current example of proposals for international cooperation are the efforts in the World Health Organization (WHO) to begin negotiations on a treaty or agreement on the funding of biomedical R&D, based upon the principles of delinkage.